Neuromodulation Devices Market Set To Grow To $6.53 Bn By 2021

08 August 2018

Visiongain has launched a new Pharmaceutical Report: Neuromodulation Devices Report 2017-2027: Revenue Forecasts for Deep Brain Stimulation, Spinal Cord, Vagus Nerve, Sacral Nerve and Gastric Electrical Applications

The report forecasts the neuromodulation devices market will multiply in revenues from 2017 to 2027. The pharmaceutical segment is evolving. Visiongain reports the strength of the neuromodulation devices market is its spinal cord stimulation segment, which generated revenues of $1.89bn. Growth in the market will be driven by the ageing population and the increasing prevalence of age-related conditions and chronic diseases. This will drive demand from both the developing and the developed world for neuromodulation devices. In addition, better access to healthcare and new diagnostic techniques has increased the number of people being identified with conditions such as chronic pain, and increase the number of patients receiving adequate treatment. Continuous research and development will lead to more applications being found for neuromodulation devices, with an increasing trend for more-personalised healthcare. All these factors combined will drive the growth of the neuromodulation devices industry through to 2027.

‘’Neuromodulation devices provide promising treatments for illnesses including chronic pain, epilepsy, Parkinson’s disease, depression and incontinence. The neuromodulation devices market is set to experience growth over the next 10 years, driven by the ageing population and the increasing prevalence of age-related conditions and chronic diseases and better access to healthcare. Continuous research and development will lead to more applications being found for neuromodulation devices, with an increasing trend for more-personalised healthcare.
The US will retain its position as market leader, emerging countries such as China and India will also contribute to the growth of the industry as they strive to provide better healthcare, thus increasing sales of neuromodulation devices.’’ – Medical Device Industry Analyst

The new report shows revenue forecasts to 2027 at overall world market, submarket and national level. It forecasts these world-level submarkets:

• Spinal Cord Stimulation
• Sacral Nerve Stimulation
• Vagus Nerve Stimulation
• Deep Brain Stimulation
• Gastric Electric Stimulation

This investigation research, data and analyses covering activities of Medtronic, Boston Scientific
St Jude Medical (Subsidiary of Abbott Diagnostics), Cyberonics (Subsidiary of LivaNova).

Analyses cover R&D, Mergers and Acquisitions, and commercial news and predicts revenues to 2027 in leading regional markets. This includes the US, Japan, Germany, the UK, France, Italy, Spain (EU5 group), Brazil, Russia, India, China.

Neuromodulation Devices Report 2017-2027 adds to visiongain’s range of reports on industries and markets in healthcare. Together these studies cover medical devices, diagnostics and pharmaceuticals.

Leading companies featured in the report who are developing neuromodulation devices include Medtronic, Boston Scientific, St Jude Medical (Subsidiary of Abbott Diagnostics), Cyberonics (Subsidiary of LivaNova)

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes RNA Analysis/Transcriptomics Market Report 2020-2030

Rising preference for personalised medicine in developed as well developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase RNA analysis/transcriptomics market concentration over the forecast period. In order to increase the reliability and success rate of the drug production process.

30 November 2020


Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020


Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020


Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020